Advanced

Breast cancer in systemic lupus erythematosus (SLE) : receptor status and treatment

Chan, K.; Clarke, A. E.; Ramsey-Goldman, R.; Foulkes, W.; Tessier Cloutier, B.; Urowitz, M. B.; Gladman, D.; Nived, O. LU ; Romero-Diaz, J. and Petri, M., et al. (2018) In Lupus 27(1). p.120-123
Abstract

Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2... (More)

Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Breast cancer, estrogen, progesterone, receptor, systemic lupus erythematosus
in
Lupus
volume
27
issue
1
pages
4 pages
publisher
SAGE Publications Ltd
external identifiers
  • scopus:85038447514
ISSN
0961-2033
DOI
10.1177/0961203317713146
language
English
LU publication?
yes
id
76168e42-4199-4a9a-b123-f8ccc658e41a
date added to LUP
2018-01-02 15:03:05
date last changed
2018-05-29 11:02:26
@article{76168e42-4199-4a9a-b123-f8ccc658e41a,
  abstract     = {<p>Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).</p>},
  author       = {Chan, K. and Clarke, A. E. and Ramsey-Goldman, R. and Foulkes, W. and Tessier Cloutier, B. and Urowitz, M. B. and Gladman, D. and Nived, O. and Romero-Diaz, J. and Petri, M. and Ginzler, E. and Fortin, P. R. and Bae, S. C. and Wallace, D. J. and Yelin, E. H. and Bernatsky, Sasha},
  issn         = {0961-2033},
  keyword      = {Breast cancer,estrogen,progesterone,receptor,systemic lupus erythematosus},
  language     = {eng},
  month        = {01},
  number       = {1},
  pages        = {120--123},
  publisher    = {SAGE Publications Ltd},
  series       = {Lupus},
  title        = {Breast cancer in systemic lupus erythematosus (SLE) : receptor status and treatment},
  url          = {http://dx.doi.org/10.1177/0961203317713146},
  volume       = {27},
  year         = {2018},
}